AstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA Approval
AstraZeneca's treatment for adults with muscle-invasive bladder cancer was approved in the U.S.
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
PharmiWeb2h
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...